Drug Type Antibody drug conjugate (ADC) |
Synonyms Claudin 18.2 ADC - Shandong Boan Biotechnology, BA1301, PR 301 + [1] |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), Tubulin inhibitors |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 25 May 2023 | |
Esophageal Carcinoma | Phase 1 | CN | - | |
Pancreatic Cancer | Phase 1 | CN | - | |
Stomach Cancer | Phase 1 | CN | - | |
Gastrooesophageal junction cancer | Preclinical | US | 22 Jan 2024 |